| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.15 | 4e-06 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.0002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.16 | 0.0004 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |